Dyne Therapeutics (DYN) shares were up 1.7% in early trading Thursday after the company reported a Q4 net loss of $0.88 per diluted share, compared with a $1.09 loss a year earlier.
Analysts polled by FactSet expected a $0.94 loss.
The company did not report revenue for the quarter ended Dec. 31.
The company said it had $642.3 million in cash, cash equivalents and marketable securities as of Dec. 31, which together with about $140.6 million in net proceeds from a recent at-the-market offering is expected to fund operations at least into H2 of 2026.
Price: 14.03, Change: +0.24, Percent Change: +1.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.